Three experts on the treatment of schizophrenia participated in a recent series of teleconferences to discuss current evidence on the management of adverse effects via elective changes in oral antipsychotics. The goal of the project was to provide updated guidance based on findings that have become available since the publication of the 2009 Patient Outcomes Research Team (PORT) psychopharmacological treatment recommendations.
The faculty for this Brief Report series discussed the content in a peer-review planning teleconference, the chair reviewed the Brief Report series for accuracy, and a member of the Journal Editorial Board who is without conflict of interest reviewed the Brief Report series to determine whether the material is evidence-based and objective.
This Brief Report series is derived from the planning teleconference series Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice, which was held in May and June 2013.
The teleconference series was chaired by John W. Newcomer, MD, Executive Vice Dean, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida. The faculty were Peter J. Weiden, MD, Professor of Psychiatry, University of Illinois at Chicago, and Robert W. Buchanan, MD, Professor of Psychiatry, University of Maryland School of Medicine, and Interim Director, Maryland Psychiatric Research Center, Baltimore, Maryland.
Dr Newcomer has received grant/research support from the National Institutes of Health; honoraria from American Physician Institute, CME Outfitters, CMEology, and American Psychiatric Association; financial or material support from Jones and Bartlett Publishing; and has served on the Data Safety Monitoring Boards for Bristol-Myers Squibb, Merck, and Vivus. Dr Buchanan has served as a consultant for Abbott, Amgen, Bristol-Myers Squibb, EnVivo, Omeros, and Pfizer; has served on the advisory boards for Abbott, Amgen, Pfizer, and Roche; and has served on the Data Safety Monitoring Board for Pfizer. Dr Weiden has received grant/research support from Johnson & Johnson (Janssen), Genentech/Roche, Novartis, Neurocrine, and Sunovion; has served as a consultant for Delpor, Johnson & Johnson (Janssen), Genentech/Roche, Lundbeck, Otsuka, Novartis, Reckitt Benckiser, and Sunovion; and been on the speakers board for Johnson & Johnson (Janssen), Genentech/Roche, Lundbeck, Otsuka, Novartis, and Sunovion.
This evidence-based, peer-reviewed Brief Report series was prepared by Healthcare Global Village, Inc. Financial support for the teleconference and preparation of this Brief Report series was provided by an educational grant from Sunovion Pharmaceuticals, Inc. The faculty acknowledges Ruth Ross, MA, Project Manager, Healthcare Global Village, for editorial assistance in developing this Brief Report series.
The opinions expressed herein are those of the faculty and do not necessarily reflect the views of the publisher, the American Society of Clinical Psychopharmacology, Healthcare Global Village, or the commercial supporter.
© Copyright 2014 Physicians Postgraduate Press, Inc. All rights reserved.